[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100418678":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":37,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":10,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Aalborg University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patient with arthritis starting infliximab or adalimumab",null,"Patients with Rheumatoid Artritis, Psoriatic Arthritis, Anchylosing Spondylitis starting treament with infliximab or adalimumab",[13],{"name":14,"affiliation":15,"role":16},"Lene Dreyer, MD, Prof.","Department of Clinical Medicine, Aalborg University and Aalborg University Hospital","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Karen B Lauridsen, MD","CONTACT","0045 097665595","kabula@rn.dk",[24],{"facility":25,"status":26,"city":27,"state":10,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Department of rheumatology","RECRUITING","Aalborg","8000","Denmark","DK",{"type":32,"coordinates":33},"Point",[34,35],9.9187,57.048,{"lat":35,"lon":34},{"type":16,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Karen Buch Lauridsen","Principal Investigator","100418678","characterization-of-immunogenicity-of-tnf-inhibitors-in-arthritis-patients-with-poorer-treatment-response-100418678",false,"NCT04731831","Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.","Characterization of Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis Patients With Poorer Treatment Response Due to Gender, Obesity and Smoking Status.","Inclusion Criteria:\n\n* Patients \\> 18 years\n* Diagnosed with RA, PsA or AS.\n* Starting treatment with infliximab or adalimumab.\n* Co- treatment with csDMARD or glucocorticoid is acceptable.\n* No new bDMARD is initiated at the time of sampling.\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":50,"type":51},120,"ESTIMATED","OBSERVATIONAL","The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.",[55,56,57],"Arthritis, Rheumatoid","Arthritis, Psoriatic","Spondylitis, Ankylosing","2024-06-27",{"date":60,"type":61},"2024-06-28","ACTUAL",{"date":63,"type":61},"2020-08-01",{"date":65,"type":51},"2025-12-30",{"name":5,"class":6},1]